Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Feb 28;12(2):209-212.
doi: 10.21037/tcr-22-2926. Epub 2023 Feb 1.

Can we cure metastatic EGFR-mutated lung cancer today?

Petros Christopoulos  1   2
Affiliations
Editorial

Can we cure metastatic EGFR-mutated lung cancer today?

Petros Christopoulos. Transl Cancer Res. .
No abstract available

Keywords: Epidermal growth factor receptor lung cancer (EGFR lung cancer); biomarkers; long-term survival; tyrosine kinase inhibitors (TKI).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The author has completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-22-2926/coif). The author declares research funding from AstraZeneca, Amgen, Merck, Novartis, Roche, and Takeda; speaker’s honoraria from AstraZeneca, Novartis, Pfizer, Roche, Takeda; support for attending meetings from AstraZeneca, Daiichi Sankyo, Eli Lilly, Gilead, Janssen, Novartis, Takeda; and personal fees for participating to advisory boards from Boehringer Ingelheim, Chugai, Pfizer and Roche; all outside the submitted work. The author has no other conflicts of interest to declare.

Comment on

References

    1. Chakravarty D, Johnson A, Sklar J, et al. Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion. J Clin Oncol 2022;40:1231-58. 10.1200/JCO.21.02767 - DOI - PubMed
    1. Magios N, Bozorgmehr F, Volckmar AL, et al. Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer. Ther Adv Med Oncol 2021;13:1758835921996509. 10.1177/1758835921996509 - DOI - PMC - PubMed
    1. Wan Y, Xu F, Wang J. Long-term survival of a non-small cell lung cancer patient with EGFR-mutated brain metastases: a case report. Transl Cancer Res 2022;11:4448-54. 10.21037/tcr-22-1671 - DOI - PMC - PubMed
    1. Christopoulos P, Kirchner M, Roeper J, et al. Risk stratification of EGFR(+) lung cancer diagnosed with panel-based next-generation sequencing. Lung Cancer 2020;148:105-12. 10.1016/j.lungcan.2020.08.007 - DOI - PubMed
    1. Xiao J, Zhou L, He B, et al. Impact of Sex and Smoking on the Efficacy of EGFR-TKIs in Terms of Overall Survival in Non-small-Cell Lung Cancer: A Meta-Analysis. Front Oncol 2020;10:1531. 10.3389/fonc.2020.01531 - DOI - PMC - PubMed